# Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS

> **NCT05175508** · PHASE2,PHASE3 · UNKNOWN · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 180 (estimated)

## Conditions studied

- AML
- MDS
- Old Age; Debility
- Hematologic Cancer

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** all trans retinoic acid

## Key facts

- **NCT ID:** NCT05175508
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-01
- **Primary completion:** 2022-05-01
- **Final completion:** 2023-05-01
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2022-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05175508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05175508, "Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05175508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*